Abstract Objective To study the clinical features of severe type 7 adenovirus pneumonia in children. Methods A retrospective analysis was performed for the clinical data of children who were diagnosed with severe type 7 adenovirus pneumonia from February to June, 2019. Results Among the 45 children, the male/female ratio was 3:2 and the median age was 14 months. All children had repeated fever, cough, and pulmonary moist rales, and the mean duration of fever was 14±4 days. The median time from fever to dyspnea was 8 days, and the time from fever to mechanical ventilation was 11.6±2.5 d. There was no significant increase in white blood cell count, with neutrophils as the main type. There were slight reductions in hemoglobin and albumin, while platelet and fibrinogen remained normal. There were increases in aspartate aminotransferase, lactate dehydrogenase, procalcitonin, and C-reaction protein. The detection rate of mixed pathogens was 84%. Effusion in both lungs was the major change on chest imaging (64%). Bronchoscopic manifestations were endobronchitis, tracheomalacia, and plastic bronchitis. The incidence rate of respiratory complications was 100%, and extrapulmonary complications mainly involved the circulatory system (47%), digestive system (36%), and nervous system (31%). Among the 45 children, 16 were administered with 400 mg/kg intravenous immunoglobulin (IVIG) daily for 5 days, with a mean duration of fever of 16±5 days, and 29 were administered with 1 g/kg IVIG daily for 2 days, with a mean duration of fever of 13±4 days; there was a significant difference in the mean duration of fever between the two groups (P=0.046). The overall mortality rate was 11%. Conclusions Severe type 7 adenovirus pneumonia in children has severe conditions, with a high incidence rate of complications and a high mortality rate, so it should be diagnosed and treated as early as possible.
ZHANG Xin-Ping,YANG Mei-Yu,ZHOU Xiong et al. Clinical features of severe type 7 adenovirus pneumonia: an analysis of 45 cases[J]. CJCP, 2020, 22(5): 429-434.
ZHANG Xin-Ping,YANG Mei-Yu,ZHOU Xiong et al. Clinical features of severe type 7 adenovirus pneumonia: an analysis of 45 cases[J]. CJCP, 2020, 22(5): 429-434.
Binder AM, Biggs HM, Haynes AK, et al. Human adenovirus surveillance-United States, 2003-2016[J]. MMWR Morb Mortal Wkly Rep, 2017, 66(39):1039-1042.
[4]
Cheng JL, Peng CC, Chiu NC, et al. Risk factor analysis and molecular epidemiology of respiratory adenovirus infections among children in northern Taiwan, 2009-2013[J]. J Microbiol Immunol Infect, 2017, 50(4):418-426.
[5]
Scott MK, Chommanard C, Lu X, et al. Human adenovirus associated with severe respiratory infection, Oregon, USA, 2013-2014[J]. Emerg Infect Dis, 2016, 22(6):1044-1051.
[6]
Zhao S, Wan C, Ke C, et al. Re-emergent human adenovirus genome type 7d caused an acute respiratory disease outbreak in Southern China after a twenty-one year absence[J]. Sci Rep, 2014, 4:7365.
Oumei H, Xuefeng W, Jianping L, et al. Etiology of community-acquired pneumonia in 1500 hospitalized children[J]. J Med Virol, 2018, 90(3):421-428.
[10]
Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children[J]. N Engl J Med, 2015, 372(9):835-845.
[11]
Cherry JD, Harrison GJ, Kaplan SL, et al. Feigin & Cherry's textbook of pediatric infectious diseases[M]. 7th ed. Philadelphia:Saunders, 2014:1888-1911.
[12]
Lai CY, Lee CJ, Lu CY, et al. Adenovirus serotype 3 and 7 infection with acute respiratory failure in children in Taiwan, 2010-2011[J]. PLoS One, 2013, 8(1):e53614.
[13]
Spaeder MC, Fackler JC. Hospital-acquired viral infection increases mortality in children with severe viral respiratory infection[J]. Pediatr Crit Care Med, 2011, 12(6):e317-e321.
Kim SJ, Kim K, Park SB, et al. Outcomes of early administration of cidofovir in non-immunocompromised patients with severe adenovirus pneumonia[J]. PLoS One, 2015, 10(4):e122642.
[22]
Yoon HY, Cho HH, Ryu YJ. Adenovirus pneumonia treated with Cidofovir in an immunocompetent high school senior[J]. Respir Med Case Rep, 2019, 26:215-218.
